Chronic hepatitis C is curable disease. Low detection rate could be one of the reasons of poor treatment uptake. It is important to identify HCV prevalence and anti-hepatitis C virus (HCV) positive patients in population by effective screening strategy such as risk-based or birth cohort screening programs. There are no national population-based estimates of the HCV prevalence in the Czech Republic (CZ). The most recent seroprevalence survey determined a prevalence of positive anti-HCV antibodies of 0.2% (in 2001). The aim of the study was to determine the seroprevalence of HCV, HCV viraemia and HCV genotype in the CZ adult population. We also estimated the number of persons living with chronic hepatitis C in CZ. The examined group included 3000 adults, 18-90 years of age enrolled in 2015. All serum samples were examined to determined anti-HCV antibodies positivity, HCV-RNA positivity and genotypes. Of the 3000 samples, 50 were found to be anti-HCV-positive, for a seroprevalence of 1.67% (2.39% in males, 0.98% in females). The overall prevalence of positive HCV RNA was 0.93%: 1.5% in males, 0.39% in females. HCV genotype (GT) 1a was determined in 25%, GT 1b in 25% and GT 3a in 46%. Since 2001, the HCV seroprevalence has increased 8-fold. The highest HCV seroprevalence occurred in males aged 30-44 years. We can estimate that there are more than 140,000 people with HCV antibodies and more than 80,000 people with chronic hepatitis C living in the CZ. The introduction of birth cohort HCV screening could be beneficial for the country.

Department of Clinical Chemistry and Diagnostics University Hospital Hradec Kralove Czech Republic

Department of Clinical Microbiology University Hospital Hradec Kralove Czech Republic

Department of Epidemiology Faculty of Military Health Sciences University of Defence Hradec Kralove Czech Republic

Department of Infectious Diseases Charles University Medical Faculty and University Hospital Hradec Kralove Czech Republic

Military Health Institute Prague Czech Republic

Zobrazit více v PubMed

Omland LH, Jepsen P, Krarup H, Schonning K, Lind B, Kromann-Andersen H, et al. Increased mortality among persons infected with hepatitis C virus. Clin Gastroenterol Hepatol. 2011; 9: 71–8. doi: 10.1016/j.cgh.2010.09.014 PubMed DOI

Omland LH, Krarup H, Jepsen P, Georgsen J, Harritshoj LH, Riisom K, et al. Mortality in patients with chronic and cleared hepatitis C viral infection: a nationwide cohort study. J Hepatol. 2010; 53: 36–42. doi: 10.1016/j.jhep.2010.01.033 PubMed DOI

Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45: 529–538. doi: 10.1016/j.jhep.2006.05.013 PubMed DOI

Negro F. Epidemiology of hepatitis C in Europe, Dig Liver Dis. 2014;46 (Suppl5): S158–S164. PubMed

World Health Organization. Hepatitis C–global prevalence (update). Weekly Epidemiological Record. 1999;74: 425–27. PubMed

Deuffic-Burban S, Deltenre P, Buti M, Stroffolini T, Parkes J, Muhlberger N, et al. Predicted effects of treatment for HCV infection vary among European countries. Gastroenterology. 2012;143: 974–985, e14. doi: 10.1053/j.gastro.2012.05.054 PubMed DOI

Muhlberger N, Schwarzer R, Lettmeier B, Sroczynski G, Zeuzem S, Siebert U. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health. 2009;9: 34 doi: 10.1186/1471-2458-9-34 PubMed DOI PMC

Cornberg M, Razavi HA, Alberti A, Bernasconi E, Buti M, Cooper C, et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int. 2011;31(Suppl 2): 30–60. PubMed

Kartashev V, Döring M, Nieto L, Coletta E, Kaiser R, Sierra S. New findings in HCV genotype distribution in selected West European, Russian and Israeli regions. J Clin Virol. 2016;81: 82–9. doi: 10.1016/j.jcv.2016.05.010 PubMed DOI

Schroter M, Zollner B, Schafer P, Reimer A, Müller M, Laufs R, et al. Epidemiological dynamics of hepatitis C virus among 747 German individuals: new subtypes on the advance. J Clin Microbiol. 2002; 40: 1866–8. doi: 10.1128/JCM.40.5.1866-1868.2002 PubMed DOI PMC

Ross RS, Viazov SO, Holtzer CD, Beyou A, Monnet A, Mazure C, et al. Genotyping of hepatitis C virus isolates using CLIP sequencing. J Clin Microbiol. 2000; 38: 3581–4. PubMed PMC

Raptopoulou M, Touloumi G, Tzourmakliotis D. Significant epidemiological changes in chronic hepatitis C infection: results of the nationwide HEPNET-GREECE cohort study. Hippokratia. 2011;15: 26–31. PubMed PMC

Chlabicz S, Flisiak R, Kowalczuk O, Grzeszczuk A, Pytel-Krolczuk B, Prokopowicz D, et al. Changing HCV genotypes distribution in Poland–relation to source and time of infection. J Clin Virol. 2008; 42: 156–9. doi: 10.1016/j.jcv.2008.02.001 PubMed DOI

Prasad L, Spicher VM, Zwahlen M, Rickenbach M, Helbling B, Negro F, et al. Cohort Profile: The Swiss Hepatitis C Cohort Study (SCCS). Int J Epidemiol. 2007; 36: 731–7. doi: 10.1093/ije/dym096 PubMed DOI

Costella, Annastella and Health Protection Agency United Kingdom. Hepatitis C in the UK 2008. The Health Protection Agency Annual Report. Health Protection Agency Centre for Infections, London, 2008.

Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61: 77–87. doi: 10.1002/hep.27259 PubMed DOI PMC

Krekulova L, Rehak V, Madrigal N, Johnson M, Killoran P, Riley LW. Genotypic and epidemiologic characteristics of hepatitis C virus infections among recent injection drug user and nonuser populations. Clin Infect Dis. 2001; 33: 1435–8. doi: 10.1086/323199 PubMed DOI

National Health Institute. Infection in the Czech Republic–EPIDAT. Available from: http://www.szu.cz/publikace/data/vybrane-infekcni-nemoci-v-cr-v-letech-2006-2015-absolutne

Chlíbek R. Viral hepatitis C in General practitioner surgeries. Practicus. 2014;8: 14–15.

Nemecek V, Castkova J, Fritz P, Linhartova A, Svandova E, Sramova H, et al. The 2001 serological survey in the Czech Republic-viral hepatitis. Cent Eur J Public Health. 2003; 11 Suppl: S54–S61. PubMed

Nemecek V, Strunecky O: Genotypic Heterogeneity of Hepatitis C virus (HCV) from Blood Donors in the Czech Republic. Epidemiologie, mikrobiologie, imunologie. Epidemiol. Mikrobiol. Imunol. 2009;58(2): 63–72. PubMed

Sperl J,Frankova S, Trunecka P. Liver transplantation for chronic C hepatitis, significance for antivirus treatments. Gastroenterologie a Hepatologie. 2013;67(5): 407–412.

Schréter I, Kristian P, Klement C, Kohútová D, Jarčuška P, Maďarová L, et al. Prevalencia infekcie vírusom hepatitídy C v Slovenskej republike (Prevalence of HCV infection in the Slovak Republic) Klin Mikrobiol Inf Lek. 2007;13(2): 54–58. PubMed

Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Teo CG, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. MMWR Morb Mortal Wkly Rep. 2012;61(RR-4): 1–32. PubMed

Wolffram I, Petroff D, Bätz O, Jedrysiak K, Kramer J, Tenckhoff H, et al. Prevalence of elevated ALT values, HBsAg, and anti-HCV in the primary care setting and evaluation of guideline defined hepatitis risk scenarios. J Hepatol. 2015;62(6): 1256–64. doi: 10.1016/j.jhep.2015.01.011 PubMed DOI

Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, et al. The present and future disease burden of hepatitis C virus with today´s treatment paradigm. J Viral Hepat. 2014;21(Suppl.1): 34–59. PubMed

Christensen PB1, Hay G, Jepsen P, Omland LH, Just SA, Krarup HB, et al. Hepatitis C prevalence in Denmark -an estimate based on multiple national registers. BMC Infect Dis. 2012;6(12): 178. PubMed PMC

Jonas G, Pelzer C, Beckert C, Hausmann M, Kapprell HP. Performance characteristics of the ARCHITECT anti-HCV assay. J Clin Virol. 2005;34(2): 97–103. doi: 10.1016/j.jcv.2005.08.001 PubMed DOI

Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol. 1992;73: 673–679. doi: 10.1099/0022-1317-73-3-673 PubMed DOI

Ministry of Health, Czech Republic. Zpráva o zdraví obyvatel ČR (Health Report of the Czech population), Praha 2014:113–119. ISBN 978-80-85047-49-3.

EASL Recommendations on Treatment of Hepatitis C 2014. Available form: http://files.easl.eu/easl-recommendations-on-treatment-of-hepatitis-C.pdf.

Predictors of Significant Liver Fibrosis in People with Chronic Hepatitis C Who Inject Drugs in the Czech Republic

Therapy of chronic hepatitis C in people who inject drugs: focus on adherence

How close are we to hepatitis C virus elimination in Central Europe?

Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis